Clinical Research Directory
Browse clinical research sites, groups, and studies.
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
Sponsor: Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.
Official title: A Nonrandomized Trial Using DNA Liquid Biopsies to Guide Anticoagulation For Patients With Cancer-Associated Thromboembolism
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
259
Start Date
2026-01-30
Completion Date
2030-01-30
Last Updated
2026-02-12
Healthy Volunteers
No
Interventions
MSK-ACCESS
MSK-ACCESS is a ctDNA sequencing assay
ctDNA/VTE Risk Score:
Machine learning Venous Thromboembolism/VTE risk score mode
Locations (8)
Memorial Sloan Kettering Cancer Center Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, United States
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
Commack, New York, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
New York, New York, United States
Memorial Sloan Kettering Nassau (All protocol activities)
Rockville Centre, New York, United States
Royal North Shore Hospital, Australia
Sydney, Australia